Table 2.

Cell migration expressed with time to heal 50% of the wound (T50) and p-values.

	T50 (h) [CI95%]	p-value (Vs Control)	p-value (Vs 10 Gy)	p-value (Vs Cetuximab)
SQ20B
Control	15.5 [12.9–18.1]	—	—	—
Pertuzumab	15.4 [12.8–17.9]	0.94	—	—
Cetuximab	37.8 [31.5–44.1]	<0.001	—	—
Cetuximab + Pertuzumab	52.6 [43.4–61.8]	<0.001	—	0.0086
10 Gy	19.7 [15.8–23.6]	—	—	—
10 Gy + Pertuzumab	17 [13.7–20.3]	—	0.3	—
10 Gy + Cetuximab	43.6 [34.9–52.2]	—	<0.001	—
10 Gy + Cetuximab + Pertuzumab	69.3 [54.4–84.2]	—	<0.001	0.0013
SQ20B-CSCs
Control	20 [13.3–26.6]	—	—	—
Pertuzumab	23.7 [15.6–31.7]	0.49	—	—
Cetuximab	19.2 [12.7–25.7]	0.86	—	—
Cetuximab + Pertuzumab	54.8 [36.2–73.4]	<0.001	—	<0.001
10 Gy	20.9 [13.8–27.9]	—	—	—
10 Gy + Pertuzumab	31.4 [20.8–41.9]	—	0.093	—
10 Gy + Cetuximab	19 [12.5–24.5]	—	0.7	—
10 Gy + Cetuximab + Pertuzumab	71.1 [45.6–96.6]	—	<0.001	<0.001
FaDu
Control	16.3 [11.8–20.8]	—	—	—
Pertuzumab	15.8 [11.5–20.1]	0.89	—	—
Cetuximab	31 [22.6–39.4]	0.0011	—	—
Cetuximab + Pertuzumab	46 [33.4–58.5]	<0.001	—	0.0491
10 Gy	17.1 [12.4–21.8]	—	—	—
10 Gy + Pertuzumab	23.2 [16.9–29.5]	—	0.11	—
10 Gy + Cetuximab	31.6 [22.9–40.2]	—	0.0017	—
10 Gy + Cetuximab + Pertuzumab	99.6 [70.2–129]	—	<0.001	<0.001

Leg. T50 (h): time to heal 50% of the wound in hours; CI95%: confidence interval; Vs: versus; Gy: Gray.